Postes actifs de Ping Zhu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Directeur/Membre du Conseil | - | - |
| Directeur Technique/Scientifique/R&D | 01/08/2021 | - | |
| President | 01/08/2021 | - | |
| Corporate Officer/Principal | 01/01/2012 | 30/08/2021 |
Historique de carrière de Ping Zhu
Formation de Ping Zhu
| Shanghai Second Medical University | Undergraduate Degree |
| University of Karlsruhe | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 2 |
| Chine | 2 |
| Allemagne | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
